SK-129 is a blood-brain barrier-permeable inhibitor of alpha-synuclein (alphaS) oligomers with a Kd of 221 nM. SK-129 preferentially binds to neurotoxic alphaS oligomers over physiological alphaS monomers, inhibits alphaS aggregation, blocks the interaction and co-aggregation of alphaS with tau protein, and prevents the maturation of alphaS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinsons disease (PD) and Lewy body dementia (LBD)[1].
Molekulargewicht:
1006.92
CAS Nummer:
[1919889-97-6]
Formel:
C51H42N8O15
Target-Kategorie:
Reactive Oxygen Species (ROS),Tyrosine Hydroxylase,alpha-synuclein
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
